Clinical utility of gadoxetate disodium-enhanced hepatic MRI for stereotactic body radiotherapy of hepatocellular carcinoma
Clinical utility of gadoxetate disodium-enhanced hepatic MRI for stereotactic body radiotherapy of hepatocellular carcinoma
复制标题
DOI：
10.1007/s11604-015-0465-7
复制
发表时间：
2015-10-01
影响因子：
2.1
通讯作者：
Awai, Kazuo
中科院分区：
文献类型：
--
作者：
Nakamura, Yuko;Kimura, Tomoki;Awai, Kazuo
为探讨钆塞酸二钠增强肝脏MRI（EOB-MRI）在立体定向放射治疗（SBRT）中的应用价值，将30例接受SBRT的肝癌患者分为A组（SBRT后6个月Child-Pugh评分无变化）和B组（SBRT后6个月Child-Pugh评分增加）。在SBRT前和SBRT后6个月进行EOB-MRI。我们计算了肝胆期扫描上每个辐射剂量区域的肝脾对比度（LSC）比（使用SBRT前获得的图像之前的LSC和使用SBRT后获得的图像之后的LSC）和加权LSC（W-LSC）：[（平均LSC之前（0- 30戈伊）x肝脏体积（0 - 30戈伊）+平均LSC之前（30戈伊-）x肝脏体积（30戈伊-））/总肝脏体积]。比较两组的W-LSC、> 20戈伊照射的肝脏体积百分比（V20）和平均肝脏剂量，发现48、40和30戈伊照射后的LSC明显低于未照射的肝脏面积（p < 0.01）。单因素分析显示，只有W-LSC与B组显著相关（p = 0.02），W-LSC是预测SBRT后肝功能变化的有用参数。
To investigate the utility of gadoxetate disodium-enhanced hepatic MRI (EOB-MRI) for stereotactic body radiotherapy (SBRT) to treat hepatocellular carcinoma (HCC).We divided 30 HCC patients who underwent SBRT into group A (no change in their Child-Pugh score 6 months post-SBRT) and group B (increased score 6 months post-SBRT). EOB-MRI was performed before and 6 months after SBRT. We calculated the liver-spleen contrast (LSC) ratio for each radiation dose area on hepatobiliary phase scans (LSCbefore using images obtained before SBRT and LSCafter using images acquired after SBRT) and the weighted LSC (W-LSC) as: [(mean LSCbefore (0-30 Gy) x liver volume (0-30 Gy) + mean LSCbefore (30 Gy-) x liver volume (30 Gy-))/total liver volume]. Then we compared the W-LSC, percentage of the liver volume exposed to > 20 Gy (V20), and mean liver dose in the two groups.The LSCafter at 48, 40, and 30 Gy to the liver was statistically lower than the unirradiated area of the liver (p < 0.01). Univariate analysis showed that only W-LSC was significantly associated with group B (p = 0.02).W-LSC was a useful parameter for predicting changes in hepatic function after SBRT.